10 papers in the library · 14 citations · publishing 2025-2026
ACS Medicinal Chemistry Letters January 9, 2025 Ram W. Sabnis 7 citations
No Summary
ACS Medicinal Chemistry Letters June 12, 2025 Ram W. Sabnis 4 citations
A new class of indole derivatives has been developed as serotonergic psychedelic agents. These compounds, along with pharmaceutical compositions containing them, are intended for use in treating psychosis, mental illness, and other central nervous system disorders. The work also describes processes for preparing these novel compounds.
ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
No Summary
ACS Medicinal Chemistry Letters July 3, 2026 Ram W. Sabnis, Anika R. Sabnis
The document describes novel 6,5-bicyclic compounds that act as agonists of the 5-HT2A receptor. It covers pharmaceutical compositions containing these compounds, their potential use in treating depression, anxiety, substance abuse, and headaches, and processes for synthesizing them. This is a patent or chemical disclosure focused on drug discovery and pharmacology, not an empirical study with results.
ACS Medicinal Chemistry Letters June 3, 2026 Ram W. Sabnis, Anika R. Sabnis
This patent describes novel 5,6-bicyclic compounds that act as agonists of the 5-HT2A receptor. These compounds are intended for use in pharmaceutical compositions to treat conditions such as depression, anxiety, substance abuse, and headaches. The document also outlines processes for synthesizing these compounds. No experimental data, results, or clinical findings are presented.
ACS Med Chem Lett April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
No Summary
ACS Medicinal Chemistry Letters October 22, 2025 Ram W. Sabnis
This work describes novel psilocin derivatives designed as serotonergic psychedelic agents. It covers pharmaceutical compositions containing these compounds, their use in treating central nervous system disorders, and processes for preparing them.
ACS Medicinal Chemistry Letters August 25, 2025 Ram W. Sabnis
This patent document describes new chemical compounds that act as agonists at the 5-HT2A serotonin receptor, classifying them as serotonergic psychedelic agents. It claims pharmaceutical compositions containing these compounds and their use in treating psychosis, mental illness, and other central nervous system disorders. The document also outlines processes for synthesizing these compounds. The claims are technical and legal in nature, asserting novel chemical entities and their potential therapeutic applications, but no experimental data, clinical results, or evidence of efficacy are provided in this text.
ACS Med Chem Lett February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
The text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.
ACS Med Chem Lett January 4, 2025 Ram W. Sabnis
The text describes a class of novel chemical compounds, 3-cycloaminoindoles, that act as serotonergic psychedelic agents. These compounds are proposed for potential therapeutic use in treating psychosis, mental illness, and other central nervous system (CNS) disorders. The abstract indicates the compounds are designed to interact with serotonin receptors, a common target for psychedelic and psychiatric drugs, but provides no experimental data, results, or evidence of efficacy.